MEI Pharma Inc (MEIP): Market Cap to Revenue

Brandmark of MEI Pharma Corp (MEIP)

MEI Pharma, Inc. (MEIP) is currently in the clinical development stage, fully outsourcing synthesis and testing to external contractors. The fundamental P/S ratio confirms the current market valuation, with the metric settling at 0.30. Future earnings are based on the market launch of targeted anti-tumor agents, while an extensive network of partner laboratories minimizes operational risks during early-stage research.

MEIP MEI Pharma P/S Multiple (07/04/2022 - 11/13/2024)

Metric breakdowns and analytics for MEI Pharma Corp (MEIP)

- stock price and consensus target price:
Share Price meipharma.com|MEIP - Price Target Chart
- stock exchange capitalization data:
Market Valuation MEI Pharma Corp|MEIP - Enterprise Value
- book value of equity indicators:
Net Asset Value per Share MEI Pharma|MEIP - Book Capitalization|Market Capitalization to Book Value meipharma.com|MEIP - Cumulative Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio MEI Pharma, Inc.|MEIP - Long-Term Debt to Equity|Current Liabilities to Equity MEI Pharma Corporation|MEIP - Company Aggregate Debts|Debt to Net Assets Ratio MEI Pharma Corp|MEIP - Company Long-Term Debts|Company Short-Term Debts MEI Pharma|Intermediate Coverage Ratio meipharma.com
- earnings and multiples data:
MEIP - Company Net Income|Future Profit MEI Pharma, Inc.|MEIP - P/E Multiple|Forward P/E Multiple MEI Pharma Inc|MEIP - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation MEI Pharma Corp|MEIP - Operating profit EBITDA|Net earnings per share for the last four quarters MEI Pharma|MEIP - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months meipharma.com|MEIP - Earnings growth in current year|Expected earnings per share growth for next year MEI Pharma, Inc.
- issuer revenue and sales details:
MEIP - Company Sales|Company Future Sales meipharma.com|MEIP - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple MEI Pharma Corp
General company analysis:meipharma.com, MEIP
Finished products of MEI Pharma Inc

The P/S multiple compares a business's market value to its annual revenue, demonstrating how much investors are willing to pay per unit of sales to assess the asset's fundamental attractiveness. Analyzing the current P/S ratio reveals how the professional standing of MEI Pharma, Inc. (MEIP) as an oncology drug developer dampens the metric's volatility, reflecting market confidence in the company's clinical trial strategy.

Competing companies

tgtherapeutics.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Arcellx, Inc. ACLX|IRON - Market Cap to Revenue|Syndax - P/S Multiple|Price to Sales Kura|ADCT: P/S Multiple|FHTX - Price-to-Revenue Coefficient|Market Cap to Revenue VOR|NKTX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Coeptis Therapeutics (COEP)|ATNM: Price-to-Sales Ratio|P/S Multiple ESLA (Estrella Immunopharma)|Market Capitalization-to-Revenue Ratio CASI|Marker Bio - P/S Multiple|INAB - P/S Multiple|eternatx.com (ERNA) - Price-to-Revenue Ratio|GT Biopharma Corporation - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Aptose Biosciences Inc|Market Cap to Revenue biopathholdings.com (BPTH)|P/S Multiple VINC